When does Tecentriq (atezolizumab) lose exclusivity in the US?
Tecentriq’s “loss of exclusivity” in the US is driven by patent and exclusivity expirations tied to its marketing authorization and specific formulations/use claims, but the exact date depends on which protection you mean (for example, drug substance patents vs. formulation/combination patents vs. regulatory exclusivities). No specific exclusivity date is provided in the information available here, so it isn’t possible to state an exact “expires on” date from the provided material alone.
What “loss of exclusivity” usually includes for a biologic like Tecentriq
For the US, “loss of exclusivity” typically refers to the point at which a competitor can launch a biosimilar without running into remaining legal barriers tied to:
- Patents listed in the FDA’s Orange Book (or relevant patent listings under the biosimilar pathway, depending on the product and protection).
- Any remaining regulatory exclusivities (when applicable).
- Additional patents that can still be asserted around manufacturing, formulation, or specific therapeutic claims.
Because Tecentriq is a biologic, the practical question for launch timing is usually patent status and biosimilar litigation/settlement history—not just a single generic “expiration date.”
Can a biosimilar enter before all patents expire?
Sometimes. Even if some patents remain, a biosimilar may still be able to launch if the remaining patents are not enforceable against the biosimilar’s intended commercial activity (or if there is a litigation outcome/settlement that allows earlier entry). The timing can therefore differ from the earliest patent expiration date.
Why people ask this specifically: biosimilar launch timing and pricing pressure
When Tecentriq approaches exclusivity end, competitors and payers typically look for:
- Biosimilar or interchangeable biologic availability in the US.
- Potential shifts in net prices and formulary position.
- Changes to access programs or contracting terms.
The actual market impact often depends on launch date and payer contracting, not only on the legal exclusivity end.
What you can check to get the exact US “loss of exclusivity” date
To determine the exact date for Tecentriq in the US, you (or a researcher) typically pull:
- FDA patent listings and expiration dates for Tecentriq.
- Any biosimilar-related litigation or settlements that affect launch.
- The specific basis of “exclusivity” you care about (drug product vs. method-of-use vs. combination regimens).
If you share whether you mean (1) the first date any biosimilar could enter, (2) the date of the last key patent, or (3) a specific biosimilar applicant, I can help map which kind of protection usually controls that answer—though the specific calendar dates would still require the underlying patent/exclusivity listing details.
Sources
No source information was provided with the question, so I did not cite any materials.